Tian Xinping, Li Mengtao, Liu Shengyun, Leng Xiaomei, Wang Qian, Zhao Jiuliang, Liu Yi, Zhao Yan, Zhang Yizhi, Xu Huji, Gu Jieruo, Zeng Xiaofeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
Department of Rheumatology and Immunology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Rheumatol Immunol Res. 2023 Jul 22;4(2):47-59. doi: 10.2478/rir-2023-0009. eCollection 2023 Jun.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and they are becoming increasingly important in the treatment of SpA. However, identifying the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these "targeted therapeutic drugs". Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), managed by Peking Union Medical College Hospital, the "Consensus on targeted drug therapy for spondyloarthritis" has been developed in collaboration with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, and Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus has been developed with evidence-based methodology and has followed the international standard for consensus development.
脊柱关节炎（SpA）是一组主要累及脊柱和/或外周关节的慢性炎症性疾病。SpA的临床表现高度异质性，且伴有各种合并症，情况复杂。SpA是一种致残性疾病，对患者的生活质量产生不利影响。许多针对SpA发病机制中特定细胞因子或通路的新型药物已被研发出来，它们在SpA的治疗中变得越来越重要。然而，确定目标患者群体以及规范这些药物的使用是这些“靶向治疗药物”临床应用中的关键问题。在由北京协和医院管理的国家皮肤与免疫疾病临床医学研究中心（NCRC-DID）的领导下，与中国医师协会风湿免疫科医师分会、中华医学会风湿病学分会、中国康复医学会风湿免疫专业委员会以及中国研究型医院学会风湿免疫专业委员会合作制定了《脊柱关节炎靶向药物治疗专家共识》。本共识采用循证方法制定，并遵循国际共识制定标准。
